Sign in
Taking people in United StatesPhase 3

A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age

Key facts

Who runs it
GlaxoSmithKline
Where
DeSoto, Fort Worth, Glendale, Hartsdale, Lenexa, Meridian, Miami, Miami Lakes, San Diego, Spartanburg, Tucson, and Valparaiso, United StatesSee the 12 sites
Status
Recruiting
Phase
Phase 3
People taking part
3,000 people, planned
Started
1 Oct 2026
Expected to end
9 Jul 2027
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • mRNA Seasonal Flu vaccine
  • Comparator 1
  • Comparator 2
Record updated
9 October 2026

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits, attendance to study contacts, and ability to access and utilize a phone or other electronic communications) independently or with the assistance of a caregiver
  • A male or female participant between and including 18 to 64 years of age at the time of study intervention administration
  • Participants of childbearing potential may be enrolled, if the participant:; has practiced adequate contraception for at least 30 days prior to study intervention administration, and; has a negative urine pregnancy test within 24 hours prior to study intervention administration, and; has agreed to continue adequate contraception for at least 8 weeks after study intervention administration

Who cannot take part

  • History of test confirmed influenza infection within 180 days prior to study intervention administration
  • History of hypersensitivity or allergic reaction to any previous influenza vaccine
  • History of hypersensitivity or allergic reaction to any previous mRNA vaccine
  • History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine
  • Administration of an influenza vaccine in the period starting 180 days before the study intervention administration or planned administration prior to Visit 2 during the study
  • Planned administration/administration of prohibited vaccines within protocol-defined time windows before or after study intervention administration
  • Use of any investigational or non-registered product (other than the study intervention during the period beginning 30 days before the dose of study intervention (Day -29 to Day 1), or their planned use during the study period
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune modifying treatments at any time up to the end of the study
  • Confirmed or suspected immunosuppressive or immunodeficient condition, except for stable human immunodeficiency virus infection meeting protocol-defined stability criteria
  • History of myocarditis or pericarditis considered causally associated with the administration of an mRNA vaccine
  • Acute or unstable chronic conditions as determined by medical history and clinical examination
  • Pregnant or lactating female participant

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in United States

  • DeSoto, TexasHospital not named in the registryContact: Haresh Boghara (principal investigator)Taking people
  • Fort Worth, TexasHospital not named in the registryContact: William Seger (principal investigator)Taking people
  • Glendale, WisconsinHospital not named in the registryContact: Abram Burgher (principal investigator)Taking people
  • Hartsdale, New YorkHospital not named in the registryContact: Michael Gerdis (principal investigator)Taking people
  • Lenexa, KansasHospital not named in the registryContact: Carlos Fierro (principal investigator)Taking people
  • Meridian, IdahoHospital not named in the registryContact: Mark Turner (principal investigator)Taking people
  • Miami, FloridaHospital not named in the registryContact: Rafael Ubeda (principal investigator)Taking people
  • Miami Lakes, FloridaHospital not named in the registryContact: Jose Cardona (principal investigator)Taking people
  • San Diego, CaliforniaHospital not named in the registryContact: Donald Brandon (principal investigator)Taking people
  • Spartanburg, South CarolinaHospital not named in the registryContact: Charles Fogarty (principal investigator)Taking people
  • Tucson, ArizonaHospital not named in the registryContact: Anita Kohli (principal investigator)Taking people
  • Valparaiso, IndianaHospital not named in the registryContact: Robert Buynak (principal investigator)Taking people

About the trial

What the trial wants to find out

This clinical trial will study an investigational seasonal influenza vaccine in adults 18 to 64 years of age. The vaccine is based on messenger ribonucleic acid, also called mRNA. The main goals of the study are to learn how well the vaccine helps the body make an immune response against influenza and what medical problems participants may have after vaccination. Researchers will also compare immune responses in adults 18 to 64 years of age from this study, with immune responses in adults 65 years of age and older from another study. Participants will receive 1 injection into the upper arm muscle and will be followed for about 6 months.

The 4 groups in the trial

  • mRNA Seasonal Flu Vaccine - Cohort 1Treatment being tested

    Participants 18 to 64 years of age will receive a single dose of investigational mRNA Seasonal Flu vaccine on Day 1.

    Treatment: mRNA Seasonal Flu vaccine

  • Comparator 1_Cohort 1Existing treatment, for comparison

    Participants 18 to 64 years of age will receive a single dose of comparator 1 on Day 1.

    Treatment: Comparator 1

  • mRNA Seasonal Flu Vaccine - Cohort 2Treatment being tested

    Participants 60 to 64 years of age will receive a single dose of investigational mRNA Seasonal Flu vaccine on Day 1.

    Treatment: mRNA Seasonal Flu vaccine

  • Comparator 2_Cohort 2Existing treatment, for comparison

    Participants 60 to 64 years of age will receive a single dose of comparator 2 on Day 1.

    Treatment: Comparator 2

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 3 Randomized, Observer-Blind, Controlled Study to Evaluate the Immunogenicity, Reactogenicity and Safety of an mRNA-based Seasonal Influenza Vaccine, in Adults 18-64 Years of Age
Criteria questions
Built from NCT07851246, who can take part
Record updated
9 October 2026